SOPHiA GENETICS (SOPH) investor relations material

Leadership transition and strategic vision

• CEO transition planned for July 1, with the founder moving to executive chairman and a focus on commercial leadership to drive the next growth phase.

• The company has grown to nearly 1,000 customers in 70 countries, analyzing 35,000 genomics profiles monthly.

• Emphasis on scaling the platform, improving product-market fit, and leveraging a global network for precision medicine.

• Leadership aims to attract top talent in precision medicine and AI to support rapid scaling and innovation.

• The founder remains engaged to support the new CEO and ensure continuity.

Growth outlook and business performance

• Revenue guidance for 2026 targets 20%-22% growth, an acceleration from previous years.

• U.S. market is experiencing 50% volume growth, with potential for further acceleration as new large accounts come online.

• Biopharma segment has been rebooted, with new contracts expected to contribute significantly in 2026 and 2027.

• The company is positioned to show growth acceleration through 2026 and into 2027.

• Pharma business is under 10% of revenue but expected to become more material by 2027-2028.

Market dynamics and technology trends

• The platform serves both centralized and decentralized labs, enabling compute at scale and menu expansion globally.

• U.S. hospitals are increasingly bringing testing in-house for established, reimbursed tests, while complex or novel tests remain centralized.

• Advances in sequencing and automation have removed bottlenecks, allowing even small labs to operate at high volumes profitably.

• The company’s land-and-expand strategy leverages initial wins to drive broader adoption within major accounts.

• Applications like exomes, hereditary cancer, and liquid biopsy are seeing strong adoption and expansion potential.